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Abstract
This issue marks the 10th year anniversary of Neoplasia
where we have seen exciting growth on the impact
that Neoplasia has had on cancer research worldwide.
Neoplasia was founded in 1999 at which time manu-
scripts were accepted through e-mail. In 2000, Neoplasia
became the first journal to offer web-based online manu-
script submission and peer-review using a custom-
designed application JournalSoft. Now, the use of
web-based manuscript processing has become an in-
dustry standard as it provides authors with a rapid and
useful dialog exchange for improving the quality of
the science and the overall speed of the review pro-
cess. Moreover, during the past 10 years, the Internet
has experienced a massive growth of a complex global
grid of now over an estimated 1.2 billion Internet users
which have resulted in a major shift in the medium
of scientific communication for scholarly publishing.
Neoplasia continues to evolve with the technology
and has implemented a rapid time-to-publication sched-
ule to continue dissemination of published cancer re-
search findings quickly to the scientific community.
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Overview
During the past 3 years, Neoplasia has published consis-
tent, broad-based research and review articles from diverse
areas of cancer research (Table 1). Table 1 lists articles by
general topic area for publication years 2005 to 2007, which
reveals that the number of articles has been significantly
growing and that Neoplasia is having an important impact
in the cancer research community.
Finally, Neoplasia continues to maintain an open access
policy for all Neoplasia articles to make important discov-
eries reported within its pages available online for worldwide
readership. This provides authors with the widest possible
readership, which ensures that articles published in Neo-
plasia will have the largest impact possible within the can-
cer research and clinical communities. One metric of the
success of Open Access can be found in the Thomson Sci-
entific Impact Factor, which, for Neoplasia, has increased
to 4.9 this past year, indicating that the quality and impact
of articles published by Neoplasia are outstanding as
judged by the number of citations by other scientists. In
summary, Neoplasia is committed to continuing to meet the
ever-changing concerns and needs of cancer investigators
through implementation of leading-edge technological advances
including online peer-review and electronic hosting of articles
on PubMed Central, open access for all published articles.
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